Gilenya – AfricaNewsAnalysis

New data show Novartis’ Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients

07/10/2013 ANA 0

Novartis recently announced new data indicating that continued treatment with Gilenya® (fingolimod) led to a reduction in brain volume loss in patients with relapsing forms of multiple sclerosis (MS), and was associated with a higher […]

Data at ECTRIMS to confirm Novartis’ Gilenya® long-term efficacy on reducing brain volume loss and real-world relapse rates in MS

25/09/2013 ANA 0

New data showing the benefits of Gilenya® (fingolimod) on patient outcomes in multiple sclerosis (MS) will be presented at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) in […]

Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis

10/06/2013 ANA 0

Two new analyses from the Phase III TRANSFORMS study presented at the 23rd meeting of the European Neurological Society (ENS) in Barcelona, demonstrated how Novartis’ Gilenya® (fingolimod) was effective against all four key measures of […]